Self-administration of romiplostim in patients with chronic immune thrombocytopenia
نویسندگان
چکیده
Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City; New York Presbyterian Hospital, Departments of Pediatrics and Medicine, Division of Hematology, New York; Cancer Care Centers of South Texas/ US Oncology, San Antonio, Texas; 4 Jane Ann Nohl, Division of Hematology, University of Southern California Keck School of Medicine, Los Angeles; University of Pittsburgh (Pennsylvania) Cancer Institute; Department of Hematology, AZ Sint-Jan Brugge-Oostende, Brugge, Belgium; Amgen Inc, Thousand Oaks, California
منابع مشابه
Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia
Inhibition of platelet production and mediated by antiplatelet antibodies is a well-known mechanism causing low platelet counts in immune thrombocytopenia (ITP). Use of thrombopoietin receptor agonists increases platelet counts and decreases the risk of bleeding in patients with ITP. Two such thrombopoietin receptor agonists, romiplostim and eltrombopag, are approved by the US Food and Drug Adm...
متن کاملRomiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
PURPOSE On August 22, 2008, Romiplostim (Nplate for Injection) received approval from the US Food and Drug Administration (FDA) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. This report summarizes the FDA analyses of the clinical data sup...
متن کاملA Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study to Determine the Effect of Romiplostim on Health‐Related Quality of Life in Children with Primary Immune Thrombocytopenia and Associated Burden in Their Parents
BACKGROUND Chronic immune thrombocytopenia (ITP) in children can negatively impact their health-related quality of life (HRQoL) and impose a burden on their parents. This study sought to examine the effect of romiplostim on HRQoL and parental burden in children with primary ITP. PROCEDURE This was a phase 3, randomized, double-blind, placebo-controlled study. Children aged <18 years with ITP ...
متن کاملEvaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim.
Romiplostim is a thrombopoietin receptor agonist that increases platelet counts in patients with chronic immune thrombocytopenia (ITP). Thrombopoietin receptor agonists are reported to increase the risk for reticulin fiber deposition within bone marrow. This report describes bone marrow findings from romiplostim-treated rats, a retrospective analysis of reticulin observed in romiplostim ITP cli...
متن کاملSustained Remission in Patients with Primary Immune Thrombocytopenia after Romiplostim Tapering and Discontinuation: A Case Series in Real Life Management in Spain
Romiplostim, a thrombopoietin-receptor agonist (TPO-ra), is a highly effective option in primary immune thrombocytopenia (ITP), with 80-90% of patients achieving platelet responses after few weeks of treatment. The evidence showing remissions, that is, sustained platelet counts after romiplostim discontinuation, in patients with ITP refractory to immunosuppressive therapy is steadily increasing...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2013